The outbreak of coronavirus disease 2019 (COVID-19) in December 2019 in China, has become a pandemic in March 2020. Repurposing old and relatively safe drugs becomes an advantageous option to obtain the urgently needed effective treatment. Repurposing chloroquine, hydroxychloroquine, oseltamivir, lopinavir/ritonavir, and favipiravir, and the use of investigational drug remdesivir for treatment of COVID-19, are reviewed from the clinical pharmacology perspective, particularly its efficacy and safety. Limited clinical studies of chloroquine, hydroxychloroquine, favipiravir, and remdesivir showed some efficacy in COVID-19 treatment with tolerable adverse effects. Potential serious adverse effect of chloroquine and hydroxychloroquine is cardiac arrhythmia. Oseltamivir has no documented activity against SARS-CoV-2, while lopinavir/ritonavir showed limited efficacy in COVID-19. Currently, there is no sufficient evidence to recommend any specific anti-COVID-19 treatment. The decision to use these drugs during the COVID-19 pandemic must be based on careful consideration of the potential benefits and risks to the patient.
1 May 2024 in International Journal of Risk & Safety in Medicine
BACKGROUND: Delamanid (DLM) is a relatively new drug for drug-resistant tuberculosis (DR-TB) that has been used in Indonesia since 2019 despite its limited safety data. DLM is known to inhibit hERG potassium channel with the potential to cause QT prolongation which eventually leads to Torsades de pointes (TdP). OBJECTIVE: This study aims to analyse the changes of QTc interval in DR-TB patients on DLM regimen compared to shorter treatment regimens (STR). METHODS: A retrospective cohort was implemented on secondary data obtained from two participating hospitals. The QTc interval and the changes in QTc interval from baseline (ΔQTc) were assessed every 4 weeks for 24 weeks. RESULTS: The maximum increased of QTc interval and ΔQTc interval were smaller in the DLM group with mean difference of 18,6 (95%CI 0.3 to 37.5) and 31.6 milliseconds (95%CI 14.1 to 49.1) respectively. The proportion of QTc interval prolongation in DLM group were smaller than STR group (RR=0.62; 95%CI 0.42 to 0.93). CONCLUSION: This study has shown that DLM regimens are less likely to increase QTc interval compared to STR. However, close monitoring of the risk of QT interval prolongation needs to be carried out upon the use of QT interval prolonging antituberculoid drugs.
The COVID-19 pandemic caused by the RNA virus SARS-CoV-2, has had a significant impact not only on bodily metabolism but also at the genomic level. This study utilizes a bibliometric approach to map and identify the relationship between COVID-19 and DNA damage, genomic instability, and cell cycle deregulation. The research began with the development of in-depth research questions and conducted two rounds of literature search in the Scopus database with stringent filters to ensure relevance and accuracy. From an initial 1098 documents, 576 relevant documents were selected for further analysis. The collected data was then visualized using bibliometric methods, enabling the identification of important patterns, trends, and relationships among the research variables. Key findings indicate that DNA damage, which can induce apoptosis, is the worst impact of the infection on cells. Term frequency analysis and science mapping revealed a close relationship between "DNA damage" and "apoptosis". Furthermore, discussions on genomic instability highlight telomere regulation issues, while cell cycle deregulation during virus replication in mammalian cells indicates the importance of maintaining cell membrane integrity. This study confirms the importance of bibliometric analysis in detecting and understanding the impact of COVID-19 at the genomic level, proposing several potential research targets and enhancing our understanding of the biological response to viral infection.
5 March 2026 in Vision Science and Eye Health Journal
Introduction: Amblyopia is a condition characterized by decreased visual acuity in one or both eyes. This condition frequently occurs in children because at this stage, there is a critical period of visual development. Delayed treatment can lead to decreased or even permanent vision loss. Purpose: To determine the prevalence of refractive amblyopia in children and evaluate the effectiveness of spectacle correction on visual improvement in children aged 6-18 years diagnosed with refractive amblyopia. Methods: This was an observational analytic study with a retrospective cohort approach. The study included 29 subjects aged 6–18 years with refractive amblyopia. Visual acuity was assessed in subjects who met the inclusion criteria. Eyeglasses were prescribed and visual development was monitored. Best-corrected visual acuity (BCVA) was re-evaluated after one and six months of wearing glasses. Results: A total of 15,387 pediatric patients were screened, of whom 144 (0.94%) were diagnosed with refractive amblyopia. Twenty-nine subjects met the inclusion criteria. Significant improvements in visual acuity were observed at one month (P = 0.045) and six months (P = 0.002) after spectacle use. At one month, 37.5% of eyes improved by one line, while at six months, 31.8% showed similar improvement. The difference in effectiveness between one and six months was not statistically significant (P = 0.484). Conclusions: Spectacle correction alone is effective in improving visual acuity in children with refractive amblyopia.
Variabilitas respon obat antar pasien merupakan salah satu penyebab morbiditas dan mortalitas pada pasien. Sebagian pasien dapat mengalami adverse drug reaction (ADR) maupun efek subterapeutik pada pemberian obat. Terdapat beberapa faktor yang berkontribusi terhadap hal tersebut, salah satunya adalah variabilitas genetik antar individu. Variabilitas genetik tersebut mendorong perkembangan ilmu farmakogenomik saat ini. Farmakogenomik adalah ilmu yang mempelajari bagaimana gen memengaruhi respon individu terhadap obat. Tujuan dikembangkannya farmakogenomik adalah untuk menghasilkan pengobatan yang lebih optimal. Beberapa gen telah dibuktikan memiliki keterkaitan terhadap respon obat, yang mana dapat mempengaruhi kadar obat di dalam darah (farmakokinetik) maupun efek obat secara langsung (farmakodinamik). Perubahan farmakokinetik dan farmakodinamik obat dapat berpotensi menyebabkan toksisitas maupun penurunan efektivitas suatu obat. Tulisan ini bertujuan untuk memaparkan ketersediaan informasi variasi genetik yang telah diketahui dapat mempengaruhi respon obat, sehingga dapat membantu meningkatkan ketepatan strategi farmakoterapi